This Collaboration is Focused on Advancing the Design of the MACH-1 System, Preparing It for Phase 1 Clinical Trials

Spin-out unites three sites to create a leading global CDMO as further significant investments announced at Holmes Chapel site

SingleTimeMicroneedles wins the Food, Nutrition, and Health Category.

Health Advance Partners Agree to Equity Stake in SingleTimeMicroneedles at a $3.5 Million Valuation

SingleTimeMicroneedles to showcase STM Patch in the Food, Nutrition, and Health category

Research is currently underway to develop Cystic Fibrosis treatments

Novel sustained-release technology has potential to eliminate the need for eye drops after cataract surgery.

OcuRing™ is a novel drug delivery platform for cataract surgery with potential to eliminate the need for postoperative topical eye drops. $3M DoD award will fund IND-enabling toxicology and manufacturing activities. LayerBio plans to develop OcuRing™ products for multiple cataract surgery-related indications.

The overall growth of the rapid self-healing gel market is fueled by consistent advancements in the field of wound healing, which is also shaping up to be a primary factor that is likely to significantly influence market growth in a positive manner by 2025.

U.S. medical biomimetics market dominated North America region with more than 90% revenue share in 2018 and is anticipated to achieve significant CAGR from 2019 to 2025 owing to growing burden of chronic diseases.

Key Opinion Leader spreading awareness of diabetes endorses the company's liquid insulin mouth rinse solution for Type 2 diabetes and pre-diabetes patients

Dry powder inhalers are gaining increasing momentum for drug delivery to the lungs. One of the most used and flexible delivery technologies are capsule-based dry powder inhalers

DRAP (Drug Regulatory Authority Pakistan) provided approval to commence studies of INSUGIN in Pakistan

Non-Dilutive Investment and Product License includes licensing fee and development costs

EastGate to receive the first non-dilutive investment tranch from the total funding up to $5 million USD as per the terms of the Definitive Agreement.

In an Interview With Stock-Sector, Dr. Clarke Explains How Pulmatrix Is Targeting Major Markets With the iSPERSE Technology Platform That Delivers Drugs to the Lungs More Efficiently

Aciont's poster "Importance of the Conjunctiva in Transscleral Iontophoresis" will be shown on May 3, 2011 at the meeting.

Balbir Brar brings 25 years of drug and device development experience to Aciont Inc.

The National Eye Institute (NEI), a division of the National Institutes of Health (NIH), awarded a $2.18 million grant to Aciont Inc. to help fund its development of a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis